Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Roche’s Tecentriq gains EU approval for breast cancer

Written by: | no-reply@reuters.com | Dated: Thursday, August 29th, 2019

 

Roche immunotherapy Tecentriq gains European approval for breast cancer

 

ZURICH (Reuters) – Roche’s Tecentriq has won European approval for use against a tough-to-treat breast cancer, helping the Swiss drugmaker to widen use of an immunotherapy that has so far been eclipsed in revenue terms by more-established rival medicines.

The European Commission approved Tecentriq with Abraxane for people with metastatic triple-negative breast cancer that tests positive for a protein believed to help tumors to evade attack by the body’s immune system, Roche said on Thursday.

Tecentriq trailed rival immunotherapies Keytruda and Opdivo – produced by Merck and Bristol-Myers Squibb respectively – to market but has been racking up approvals.

These include approvals for niche indications such as metastatic triple-negative breast cancer. Some 15-20% of breast cancer is triple-negative, meaning tumors lack three characteristics for which there are more treatment options.

“The European approval of this Tecentriq combination represents a significant step forward in the treatment of this aggressive breast cancer, where the unmet medical need is great,” Roche Chief Medical Officer Sandra Horning said in a statement.

Tecentriq, having steadily added approvals in new cancer indications and new geographies, is on track to surpass $1.5 billion in annual sales in 2019, its third full year on the market.

Opdivo and Keytruda, which had a two-year head start on Tecentriq, achieved sales of $6.7 billion and $7.2 billion respectively in 2018.

 

Reporting by John Miller; Editing by David Goodman

 

Reuters source:

https://www.reuters.com/article/us-roche-tecentriq/roche-immunotherapy-tecentriq-gains-european-approval-for-breast-cancer-idUSKCN1VJ0JD

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom